Clinical Trial: Prospective, Single-Arm, Phase II Clinical Study of Ivonescimab Combined with TROP2 ADC in the Treatment of Brain Metastases from Triple-Negative Breast Cancer (China)

China, Oct. 9 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Prospective, Single-Arm, Phase II Clinical Study of Ivonescimab Combined with TROP2 ADC in the Treatment of Brain Metastases from Triple-Negative Breast Cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133876

Registration Time: 2026/10/09

Type: Interventional study

Primary Sponsor: Fudan University Shanghai Cancer Center

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=334028

Published by HT Digital Content Services with permission from Health Daily Digest....